Lower CYP2C9 activity in Turkish patients with Beh double dagger et's disease compared to healthy subjects: a down-regulation due to inflammation?

Goktas, MUSTAFA; Hatta, Fazleen; KARACA, Ozgur; KALKISIM, Said; KILIC, LEVENT; AKDOĞAN, ALİ; BABAOĞLU, MELİH; Bozkurt, ATİLLA; Hellden, Anders; Bertilsson, Leif; YAŞAR, ÜMİT

doi:10.1007/s00228-015-1899-7

Lower CYP2C9 activity in Turkish patients with Beh double dagger et's disease compared to healthy subjects: a down-regulation due to inflammation?

Goktas M. T., Hatta F., KARACA O., KALKISIM S., KILIC L., AKDOĞAN A., ...Daha Fazla

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, cilt.71, sa.10, ss.1223-1228, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 71 Sayı: 10
Basım Tarihi: 2015
Doi Numarası: 10.1007/s00228-015-1899-7
Dergi Adı: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1223-1228
Hacettepe Üniversitesi Adresli: Evet

Özet

Background We previously reported on a Swedish patient with Beh double dagger et's disease (BD) who was an ultra-rapid metaboliser of drugs catalysed by CYP2C9. Was this extreme metabolism caused by the disease?